Celltrust Corp. v. Myrepchat, LLC

CourtCourt of Appeals for the Federal Circuit
DecidedJanuary 21, 2026
Docket23-2057
StatusUnpublished

This text of Celltrust Corp. v. Myrepchat, LLC (Celltrust Corp. v. Myrepchat, LLC) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Celltrust Corp. v. Myrepchat, LLC, (Fed. Cir. 2026).

Opinion

Case: 23-2057 Document: 66 Page: 1 Filed: 01/21/2026

NOTE: This disposition is nonprecedential.

United States Court of Appeals for the Federal Circuit ______________________

CELLTRUST CORP., Plaintiff-Appellant

v.

MYREPCHAT, LLC, FKA IONLAKE, LLC, DERRICK GIRARD, WADE GIRARD, Defendants-Appellees ______________________

2023-2057 ______________________

Appeal from the United States District Court for the District of Minnesota in No. 0:19-cv-02855-WMW-DJF, Judge Wilhelmina M. Wright. ______________________

Decided: January 21, 2026 ______________________

CHRISTOPHER D. BRIGHT, Snell & Wilmer, LLP, Costa Mesa, CA, argued for plaintiff-appellant. Also represented by JING HUA.

PATRICK M. ARENZ, Robins Kaplan LLP, Minneapolis, MN, argued for defendants-appellees. Also represented by BRENDA L. JOLY, EMILY ELIZABETH NILES. ______________________ Case: 23-2057 Document: 66 Page: 2 Filed: 01/21/2026

Before PROST and CUNNINGHAM, Circuit Judges, and ANDREWS, District Judge. 1 CUNNINGHAM, Circuit Judge. CellTrust Corporation (“CellTrust”) appeals the United States District Court for the District of Minnesota’s judg- ment and its (1) denial of its motion for judgment as a mat- ter of law (“JMOL”) of infringement and validity of the asserted claims of U.S. Patent No. 9,775,012 (“’012 patent”) and U.S. Patent No. 10,778,837 (“’837 patent”); and (2) de- nial of CellTrust’s motion for a new trial and to alter or amend judgment. CellTrust Corp. v. ionLake, LLC, No. 19- CV-2855 (WMW/DJF), 2023 WL 8448792, at *14 (D. Minn. Dec. 6, 2023) (“Decision”); see also J.A. 6075–83. For the reasons below, we affirm-in-part, vacate-in-part, and re- mand. Because the parties are familiar with the general back- ground facts of this case, we focus only on the facts relevant to our discussion here. CellTrust is the owner of the ’012 and ’837 patents, which claim systems and methods for tracking electronic communications. See, e.g., ’012 patent col. 35 ll. 54–65, col. 37 l. 37 to col. 38 l. 7; ’837 patent col. 42 l. 55 to col. 43 l. 2, col. 44 ll. 22–46. CellTrust asserts claims 1, 7, 20, and 23 of the ’012 patent and claims 1, 3, 20, and 22 of the ’837 patent. The asserted claims require sending communications from a server or gateway to an electronic discovery system or enterprise information archiving sys- tem. See, e.g., ’012 patent col. 35 ll. 54–65, col. 37 l. 37 to col. 38 l. 7; ’837 patent col. 42 l. 55 to col. 43 l. 2, col. 44 ll. 22–46.

1 Honorable Richard G. Andrews, District Judge, United States District Court for the District of Delaware, sitting by designation. Case: 23-2057 Document: 66 Page: 3 Filed: 01/21/2026

CELLTRUST CORP. v. MYREPCHAT, LLC 3

CellTrust timely appealed, and we have jurisdiction under 28 U.S.C. § 1295(a)(1). I. DISCUSSION On appeal, 2 CellTrust argues that the district court erred in: (1) issuing an erroneous post-trial claim con- struction, Appellant’s Br. 16–56; (2) refusing to instruct the jury on its proposed instruction on corroboration, id. at 56–64; (3) denying JMOL for Defendants’ failure to com- ply with the corroboration requirement, id. at 65–76; (4) concluding that the jury could reach a finding of obvi- ousness based on prior art combinations not presented to the jury, id. at 76–79; and (5) entering judgment as to all claims of the ’012 and ’837 patents, rather than just the asserted claims, id. at 79. A. We first address whether the district court erred in denying JMOL of infringement of the asserted claims of the ’012 and ’837 patents. CellTrust argues that the district court erred in issuing an erroneous post-trial claim con- struction that improperly imported the limitation “di- rectly” into the asserted claims’ “sending” limitations. Appellant’s Br. 16–56. The grant or denial of a motion for JMOL is a proce- dural issue that we review under the law of the applicable regional circuit. ACCO Brands, Inc. v. ABA Locks Mfr. Co.,

2 While the appeal was pending, CellTrust moved to take judicial notice of certain aspects of the intrinsic evi- dence of the ’012 and ’837 patents. See ECF No. 45. At oral argument, CellTrust conceded that its motion for judicial notice is moot because it does not affect the outcome. Oral Arg. 15:43–16:20, https://www.cafc.uscourts.gov/oral-argu- ments/23-2057_09052025.mp3. Accordingly, we deny as moot CellTrust’s motion for judicial notice. Case: 23-2057 Document: 66 Page: 4 Filed: 01/21/2026

501 F.3d 1307, 1311 (Fed. Cir. 2007). The Eighth Circuit reviews “de novo the district court’s decision to deny judg- ment as a matter of law.” Shaw Grp., Inc. v. Marcum, 516 F.3d 1061, 1064 (8th Cir. 2008). “A determination of infringement is a question of fact that is reviewed for sub- stantial evidence when tried to a jury.” ACCO Brands, 501 F.3d at 1311. We need not address CellTrust’s claim construction ar- gument because it failed to timely raise it. A party must object to an error in a claim construction “before the jury retires in order to preserve the claim of error on appeal.” Ecolab Inc. v. Paraclipse, Inc., 285 F.3d 1362, 1369 (Fed. Cir. 2002). CellTrust did not ask the district court to construe “sending” during claim construction. J.A. 5818– 52. CellTrust also did not object to the claim constructions given to the jury. J.A. 7297 at 1370:6–8; J.A. 7666–68. Thus, the jury was entitled to apply the jury instructions it was given and “find, as a factual matter” whether the claims were infringed as written. LifeNet Health v. LifeCell Corp., 837 F.3d 1316, 1322–25 (Fed. Cir. 2016) (holding that a failure to “request a new or modified claim construction” doomed an appeal, despite a “Rule 50(a) mo- tion for JMOL” that “present[ed] the issue as a factual one.”). Under the jury instructions as given, substantial evi- dence supports the jury’s verdict. A reasonable jury could have returned a verdict of noninfringement based on the evidence presented at trial because “it was not unreasona- ble for the jury to discredit the testimony of [CellTrust’s] expert and find that the [asserted claims of the ’012 and ’837] patents were not infringed.” Star Sci., Inc. v. R.J. Reynolds Tobacco Co., 655 F.3d 1364, 1378 (Fed. Cir. 2011); Niemiec v. Union Pac. R.R. Co., 449 F.3d 854, 859 (8th Cir. 2006) (“The jury was entitled to determine what weight, if any, to give any of the expert testimony offered by the parties.”). Specifically, CellTrust’s technical expert testified that he did not look at the software or source code Case: 23-2057 Document: 66 Page: 5 Filed: 01/21/2026

CELLTRUST CORP. v. MYREPCHAT, LLC 5

on any of the accused MyRepChat servers, J.A. 6645–46 at 718:13–719:5, 719:20–720:2; he would not have been able to read code, J.A. 6634 at 707:1–3; and he did not know how the communications are sent from the accused MyRepChat server once it leaves the server. J.A. 6650 at 723:3–9. A reasonable jury could have concluded that such testimony leaves open the question of whether the ac- cused MyRepChat server directly infringes the “sending” limitations of the asserted claims.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Celltrust Corp. v. Myrepchat, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/celltrust-corp-v-myrepchat-llc-cafc-2026.